NextCell – Part of the Stem Cell Revolution

Stem and stromal cells are expected to revolutionize the treatment of today’s severe and incurable diseases. NextCell develops pioneering stromal cell therapies for the treatment of autoimmune and inflammatory diseases. NextCell's drug candidate, ProTrans, is at the forefront of our development for the treatment of type 1 diabetes.

NextCell's Product Portfolio

NextCell develops novel stromal cell therapies, with a primary focus on type 1 diabetes. The lead candidate ProTrans, is based on NextCell patented selection algorithm. NextCell also runs Cellaviva, Scandinavia's largest private stem cell bank.
Read more

About NextCell

NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem and stromal cells from umbilical cord. NextCell is focusing on research and development of novel stromal cell therapies and also runs a tissue establishment and primary biobank, classified as a healthcare provider.
Sample in a lab is being examinedRead more

Investors

NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.
Read more
Cover art of NextCell report
Read our latest report:
Interim Report 1 2023/2024
Download

News

2024-03-14

NextCell establishes QVance to meet the Nordic’s need for quality analytics

Regulatory
NextCell Pharma AB ("NextCell" or the "Company") today announces that it has formed a subsidiary company specialising in quality control analytics. QVance’s launch is a strategic addition for NextCell as the company grows its presence in the advanced therapy market. QVance will specialise in quality analyses for advanced therapeutic companies, including NextCell, in the growing cell and gene therapy market. QVance will address a large gap in the Nordic region, where there is a significant lack of local providers in this area.
Read moreRead more
2024-02-27

NextCell Pharma’s updated growth strategy

Regulatory
NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company has decided to implement strategic changes. The new strategic direction means, amongst other things, that Cellaviva will become a wholly owned subsidiary and that the company's GMP facility will have new sources of revenue. The strategic changes will also result in cost savings as a result of staff reduction.
Read moreRead more
2024-02-14

NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy

Regulatory
Today Wednesday on February 14th at 10.30 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.
Read moreRead more
2024-01-25

NextCell publishes its Interim Report 1 2023/2024

Regulatory
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2023 – November 30, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
All news

Subscribe to press releases

By filling out the form you are approving that NextCell Pharma stores your information. Read more about our integrity policy (in Swedish) here.
I am not a robot.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please try again.